RxDoctor Payments Data

Akram Kholoki, MD

Cardiovascular Disease · Valparaiso, INNPI 1164598504

Payments from drug & device makers

$11,262in general payments, 2019–2025

Across 479 payments — averaging $23.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$985
  • Medtronic$756
  • Merck$749
  • Esperion Therapeutics, Inc.$664
  • Boston Scientific$631
  • plus $6K from 41 others

What the payments were for

  • Travel & lodging$2302%
  • Food & beverage$10,89397%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,262 in reported general payments places this provider in the 70th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$323,374
Medicare patients
1,861
Services billed
6,006

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban613$667,887
EntrestoSacubitril/Valsartan168$196,505
BrilintaTicagrelor101$84,649
XareltoRivaroxaban59$71,600
MultaqDronedarone Hcl35$70,097
FarxigaDapagliflozin Propanediol52$41,528
Repatha SureclickEvolocumab15$23,743
JardianceEmpagliflozin16$20,745
NexlizetBempedoic Acid/Ezetimibe14$13,294
VerquvoVericiguat12$9,146
Metoprolol Succinate715$9,015
Repatha SyringeEvolocumab11$6,878
NexletolBempedoic Acid15$5,893
Midodrine Hcl54$5,824
Metoprolol Tartrate829$5,710

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$373$667,887613 claims
NovartisEntresto$1,291$196,505168 claims
AstraZenecaBrilinta, Farxiga$985$126,178153 claims
Johnson & JohnsonXarelto$583$71,60059 claims
Sanofi-aventis U.S. LLCMultaq$336$70,09735 claims
Boehringer IngelheimJardiance$504$20,74516 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$664$19,18729 claims
MerckVerquvo$749$9,14612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →